Azzur Group, LLC
245 First Street, Suite 1800
8 articles about Azzur Group, LLC
Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization
Editas Medicine, Inc. and Azzur Cleanrooms on Demand™, an Azzur Group company, announced the companies have expanded their multi-year contract to support the scaling of EDIT-301, Editas Medicine’s experimental cell therapy medicine under investigation for the treatment of severe sickle cell disease and transfusion-dependent beta thalassemia, from approval to commercialization.
Azzur Group Appoints Corporate Services Executive, Ray Jaffe, as Vice President of Operations, Shared Services
As the company continues to support its aggressive national growth, Azzur Group announces the appointment of Ray Jaffe to Vice President of Operations, Shared Services.
Azzur Group Welcomes FDA Veteran, Kimberley Buytaert-Hoefen, PhD, as Director of Preclinical Consulting
Dr. Buytaert-Hoefen will oversee direction and coordination of preclinical client consulting, specializing in the expansion and implementation of preclinical drug discovery and development plans from concept through preclinical studies including interactions with regulatory agencies.
Azzur Group Appoints New Leadership as Company Strengthens its Foothold throughout the United States
GxP manufacturing experts Jason Congdon and Shannon Chesterfield join Azzur Group to leader Philadelphia and San Diego consulting operations
Azzur Group opens new office in Worcester, Mass., led by Aaron Bober; Robin Elleston joins Azzur Raleigh to lead consulting practice as office expands with new training practice
Azzur Welcomes Tita Tavares as Director of Its New Office in Washington, D.C.
Chris Mansur and Ryan Ott, both Azzur Group veterans, assume new appointments following the Group's growth and further diversification.
Synlogic Expands Capabilities in Manufacturing with the Appointment of Head of Technical Operations and Establishment of In-house Production of Clinical Trial Material for its Synthetic BioticTM Medicines
Good Manufacturing Process (GMP) infrastructure enables advancement of clinical programs through early and mid-phase studies